A high-throughput sequencing study in MS patients undergoing HSCT (161) has confirmed that the CD8+ lymphocyte pool is dominated by an expansion of pre-existing clones, while the CD4+ pool is primarily comprised of lymphocytes not present pre-transplant and increased TCR diversification trended toward patient response. The gene discussed is CD4; the disease is myeloid sarcoma.